Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

S&P Futures Waver as Middle East Conflict Uncertainty Persists, U.S. Inflation Data in Focus

March S&P 500 E-Mini futures (ESH26) are trending down -0.09% this morning, swinging between gains and losses as uncertainty surrounding the Middle East conflict remains high, while investors await key U.S. inflation data.

The Middle East conflict shows no signs of easing. The price of WTI crude rose more than +4% after the UK Navy said three vessels were attacked in the Strait of Hormuz and the Persian Gulf on Wednesday, underscoring ongoing disruption to shipping. Also, U.S. Central Command said in a statement late Tuesday that American forces destroyed 16 Iranian mine-laying ships near the Strait of Hormuz....

Fundamentals

See More
  • Market Capitalization, $K 126,806,152
  • Shares Outstanding, K 254,034
  • Annual Sales, $ 12,001 M
  • Annual Income, $ 3,953 M
  • EBIT $ 4,173 M
  • EBITDA $ 4,383 M
  • 60-Month Beta 0.31
  • Price/Sales 9.76
  • Price/Cash Flow 26.22
  • Price/Book 6.26

Options Overview Details

View History
  • Implied Volatility 31.17% (+0.45%)
  • Historical Volatility 39.40%
  • IV Percentile 58%
  • IV Rank 36.23%
  • IV High 47.19% on 04/08/25
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 2) 19.08 (3.88%)
  • Put/Call Vol Ratio 1.41
  • Today's Volume 4,232
  • Volume Avg (30-Day) 4,594
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 52,247
  • Open Int (30-Day) 48,407
  • Expected Range 473.30 to 511.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 33 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.91
  • Number of Estimates 7
  • High Estimate 4.37
  • Low Estimate 3.51
  • Prior Year 3.55
  • Growth Rate Est. (year over year) +10.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
450.67 +9.26%
on 03/06/26
507.92 -3.06%
on 03/10/26
+31.14 (+6.75%)
since 02/11/26
3-Month
429.00 +14.77%
on 01/20/26
507.92 -3.06%
on 03/10/26
+46.45 (+10.42%)
since 12/11/25
52-Week
362.50 +35.83%
on 08/11/25
519.68 -5.25%
on 03/14/25
+4.04 (+0.83%)
since 03/11/25

Most Recent Stories

More News
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc

Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc

TDOC : 5.47 (-1.80%)
LASR : 66.49 (+4.23%)
MYGN : 5.06 (-1.17%)
VRTX : 492.38 (-1.36%)
NXT : 116.69 (+2.60%)
S&P Futures Waver as Middle East Conflict Uncertainty Persists, U.S. Inflation Data in Focus

March S&P 500 E-Mini futures (ESH26) are trending down -0.09% this morning, swinging between gains and losses as uncertainty surrounding the Middle East conflict remains high, while investors await key...

DDOG : 127.49 (+3.58%)
VRTX : 492.38 (-1.36%)
ORCL : 163.12 (+9.18%)
NKE : 55.70 (-0.68%)
TRI : 103.11 (-0.57%)
UNF : 274.89 (+6.58%)
ESH26 : 6,725.00 (-0.80%)
OXY : 55.58 (+4.63%)
APA : 32.97 (+3.61%)
0QWI.LN : 53.330 (+2.93%)
AVAV : 207.73 (-6.25%)
FANG : 176.64 (-0.97%)
US stocks hold steadier as Wall Street waits for the next signal on how long war with Iran may last

U.S. stocks held steadier as Wall Street waited for the next signal on when the war with Iran may end

$SPX : 6,775.80 (-0.08%)
VRTX : 492.38 (-1.36%)
WST : 238.25 (+1.89%)
$DOWI : 47,417.27 (-0.61%)
KSS : 13.79 (-5.42%)
$IUXX : 24,965.01 (+0.03%)
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today

Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today

VRTX : 492.38 (-1.36%)
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

- For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved...

VRTX : 492.38 (-1.36%)
Vertex to Participate in Upcoming March Investor Conferences

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and...

VRTX : 492.38 (-1.36%)
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral presentation at the...

VRTX : 492.38 (-1.36%)
Is Vertex Stock Outperforming the Dow?

Despite underperforming the Dow Jones Industrial Average over the past year, Vertex continues to earn moderate bullish support from analysts.

VRTX : 492.38 (-1.36%)
$DOWI : 47,417.27 (-0.61%)
BIIB : 190.48 (+1.10%)
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

NFLX : 94.89 (-2.11%)
VRTX : 492.38 (-1.36%)
GILD : 146.00 (-1.72%)
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

Get context for CRISPR Therapeutics’ Q4 results: CASGEVY launch economics, cash runway, pipeline upside, and the technical level investors should watch.

CRSP : 49.93 (-5.44%)
MS : 160.89 (+0.09%)
VRTX : 492.38 (-1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 509.02
2nd Resistance Point 504.25
1st Resistance Point 498.32
Last Price 492.38
1st Support Level 487.62
2nd Support Level 482.85
3rd Support Level 476.92

See More

52-Week High 519.68
Last Price 492.38
Fibonacci 61.8% 459.64
Fibonacci 50% 441.09
Fibonacci 38.2% 422.54
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar